{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:19:51Z","timestamp":1793380791347,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold>We sought to provide an overview of the published and currently ongoing movement disorders clinical trials employing gene therapy, defined as a technology aiming to modulate the expression of one or more genes to achieve a therapeutic benefit.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold>We systematically reviewed movement disorders gene therapy clinical trials from PubMed and<jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>using a searching strategy that included Parkinson disease (PD), Huntington disease (HD), amino acid decarboxylase (AADC) deficiency, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), dystonia, tremor, ataxia, and other movement disorders. Data extracted included study characteristics, investigational product, route of administration, safety\/tolerability, motor endpoints, and secondary outcomes (i.e., neuroimaging, biomarkers).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>We identified a total of 46 studies focusing on PD (21 published and nine ongoing), HD (2 published and 5 ongoing), AADC deficiency (4 published and 2 ongoing), MSA (2 ongoing), and PSP (1 ongoing). In PD, intraparenchymal infusion of viral vector-mediated gene therapies demonstrated to be safe and showed promising preliminary data in trials aiming at restoring the synthesis of dopamine, enhancing the production of neurotrophic factors, or modifying the functional interaction between different nodes of the basal ganglia. In HD, monthly intrathecal delivery of an antisense oligonucleotide (ASO) targeting the huntingtin protein (HTT) mRNA proved to be safe and tolerable, and demonstrated a dose-dependent reduction of the cerebrospinal fluid levels of mutated HTT, while a small phase-I study testing implantable capsules of cells engineered to synthesize ciliary neurotrophic factor failed to show consistent drug delivery. In AADC deficiency, gene replacement studies demonstrated to be relatively safe in restoring catecholamine and serotonin synthesis, with promising outcomes. Ongoing movement disorders clinical trials are focusing on a variety of gene therapy approaches including alternative viral vector serotypes, novel recombinant genes, novel delivery techniques, and ASOs for the treatment of HD, MSA, and distinct subtypes of PD (LRRK2 mutation or GBA1 mutation carriers).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>Initial phase-I and -II studies tested the safety and feasibility of gene therapy in PD, HD, and AADC deficiency. The ongoing generation of clinical trials aims to test the efficacy of these approaches and explore additional applications for gene therapy in movement disorders.<\/jats:p>","DOI":"10.3389\/fneur.2021.648532","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T05:24:00Z","timestamp":1617686640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Aristide","family":"Merola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Romagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Artusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Imbalzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber D.","family":"Van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystof","family":"Bankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","article-title":"Gene therapy for neurodegenerative disorders: advances, insights and prospects","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm Sin B."},{"key":"B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-1-60327-369-5_8","article-title":"Strategies for designing transgenic DNA constructs","volume":"1027","author":"Liu","year":"2013","journal-title":"Methods Mol Biol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int J Biomed Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral Vectors in Gene Therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1227\/NEU.0b013e3181f53a5c","article-title":"Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease","volume":"67","author":"Valles","year":"2010","journal-title":"Neurosurgery."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/hum.2011.220","article-title":"Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease","volume":"23","author":"Mittermeyer","year":"2012","journal-title":"Hum Gene Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease","volume":"85","author":"Christine","year":"2019","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease","volume":"2","author":"Niethammer","year":"2017","journal-title":"JCI Insight."},{"key":"B17","doi-asserted-by":"publisher","first-page":"eaau0713","DOI":"10.1126\/scitranslmed.aau0713","article-title":"Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity","volume":"10","author":"Niethammer","year":"2018","journal-title":"Sci Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-term follow-up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum Gene Ther Clin Dev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease","volume":"34","author":"Heiss","year":"2019","journal-title":"Mov Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"Marks","year":"2008","journal-title":"Lancet Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182904faa","article-title":"Safety\/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients","volume":"80","author":"Bartus","year":"2013","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.24436","article-title":"Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial","volume":"78","author":"Olanow","year":"2015","journal-title":"Ann Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/hum.2015.134","article-title":"Long-term safety of patients with Parkinson's disease receiving rAAV2-neurturin (CERE-120) gene transfer","volume":"27","author":"Marks","year":"2016","journal-title":"Hum Gene Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.23442","article-title":"Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains","volume":"26","author":"Bartus","year":"2011","journal-title":"Mov Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.nbd.2015.03.023","article-title":"Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with \u03b1-synucleinopathies","volume":"78","author":"Bartus","year":"2015","journal-title":"Neurobiol Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain."},{"key":"B29","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1089\/hum.2004.15.968","article-title":"Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study","volume":"15","author":"Bloch","year":"2004","journal-title":"Hum Gene Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci Transl Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien","year":"2017","journal-title":"Lancet Child Adolesc Health."},{"key":"B33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/brain\/awy331","article-title":"Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency","volume":"142","author":"Kojima","year":"2019","journal-title":"Brain."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-73870\/v1","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons","author":"Pearson","year":"2020","journal-title":"Nat Commun. [Preprint]"},{"key":"B35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.omtm.2019.07.002","article-title":"Gene Therapy for Parkinson's disease: preclinical evaluation of optimally configured TH:CH1 fusion for maximal dopamine synthesis","volume":"14","author":"Badin","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737175.2020.1763794","article-title":"Gene therapy for Parkinson's disease: contemporary practice and emerging concepts","volume":"20","author":"Merola","year":"2020","journal-title":"Expert Rev Neurother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol Ther."},{"key":"B38","unstructured":"IncVT Voyager Therapeutics Announces Preclinical Data for Huntington's Disease and Amyotrophic Lateral Sclerosis Programs at Congress of the European Society of Gene and Cell Therapy2018"},{"key":"B39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B40","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","article-title":"A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neyrodegenerative disease","volume":"27","author":"Cearley","year":"2007","journal-title":"J Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nbd.2011.10.004","article-title":"Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain","volume":"48","author":"Kells","year":"2012","journal-title":"Neurobiol Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/mt.2008.170","article-title":"Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum","volume":"16","author":"Herzog","year":"2008","journal-title":"Mol Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1136\/jnnp-2020-322904","article-title":"Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease","volume":"91","author":"Richardson","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-9139-6_8","article-title":"Intravenous infusion of AAV for widespread gene delivery to the nervous system","volume":"1950","author":"Gessler","year":"2019","journal-title":"Methods Mol Biol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.648532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T17:58:02Z","timestamp":1698861482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.648532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":44,"alternative-id":["10.3389\/fneur.2021.648532"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.648532","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"article-number":"648532"}}